YB1-PDL1
/ HKND YB1 Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 06, 2024
Irgm is A Novel Regulator of Pd-L1 Via Promoting S6K1/Ybx1 Axis in Hepatocellular Carcinoma
(APASL 2024)
- "IFN-γ-induced IRGM is a novel regulator in tumor microenvironment and HCC progression. And IRGM suppresses CD8+ CTLs infiltration and function in HCC via regulating p70S6K1/YBX1/PD-L1 axis. This study may raise a novel therapeutic strategy combined with immune checkpoint inhibitors (ICIs) against HCC."
IO biomarker • Gastrointestinal Cancer • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • CD8 • IFNG • PD-L1 • RPS6KB1 • YBX1
1 to 1
Of
1
Go to page
1